Loading…
MetaVia is projected to rise to $1.80 by 2027, a +1% move from its current price of $1.78. MTVA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.67 | $1.78 | $1.89 | -0.08% |
| Jul 14 | $1.63 | $1.78 | $1.94 | -0.15% |
| Jul 15 | $1.59 | $1.78 | $1.98 | -0.23% |
| Jul 16 | $1.56 | $1.77 | $2.01 | -0.30% |
| Jul 17 | $1.54 | $1.77 | $2.04 | -0.38% |
| Jul 18 | $1.52 | $1.77 | $2.07 | -0.46% |
| Jul 19 | $1.50 | $1.77 | $2.09 | -0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.50 | $1.77 | $2.09 | -0.53% |
| Week 2 | $1.39 | $1.76 | $2.23 | -1.06% |
| Week 3 | $1.31 | $1.75 | $2.34 | -1.59% |
| Week 4 | $1.25 | $1.74 | $2.43 | -2.11% |
| Week 5 | $1.19 | $1.73 | $2.51 | -2.63% |
| Week 6 | $1.15 | $1.72 | $2.59 | -3.15% |
| Week 7 | $1.10 | $1.71 | $2.66 | -3.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus.
DA-1726 is a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001 for moderate COVID-19; NB-01 for painful diabetic neuropathy; NB-02 for cognitive impairment; and Gemcabene for dyslipidemia. The company has a license agreement with Pfizer Inc.
for Gemcabene, and Dong-A ST is the sole manufacturer for the production of DA-1241 and DA-1726. MetaVia was formerly NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc.
in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MetaVia Inc. trades as MTVA and is currently priced at $1.73 per share, with a market capitalization of $8.93M, ranking 5166 by size. The current price and market position place the stock among small-cap biotechnology names with potential for clinical-stage development catalysts.
The long-range forecast spans multiple years, showing a path from a neutral start in 2026 to progressively higher average prices and significant upside by 2050, with 2030, 2040, and 2050 highlighting notable average prices and ROIs.
A major floor 75.7% below — a decisive break under it would weaken the trend.
The nearest floor, 19.7% below — buyers have tended to step in here.
The nearest ceiling, 74.2% above — a clean break opens room to run.
A major ceiling 116.3% above — clearing it would confirm fresh momentum.
Key MTVA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MTVA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.63 | Buy | $1.66 | Buy |
| MA 10 | $1.54 | Buy | $1.62 | Buy |
| MA 20 | $1.60 | Buy | $1.68 | Buy |
| MA 50 | $1.85 | Sell | $1.82 | Sell |
| MA 100 | $1.66 | Buy | $2.42 | Sell |
| MA 200 | $4.82 | Sell | $4.87 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.01 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 106.40 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 15.58 | Buy |
| Bollinger %B (20,2) | 0.82 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -1.10 | Sell |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 76.25 | Sell |
| Momentum (10) | 0.25 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.73 | Buy |
| ADX (14) | 16.57 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is neutral. RSI14 is 50, and the stock trades around a 30-day moving angle that sits between the SMA50 of $1.85 and the SMA200 of $4.87. Support is listed at $1.43 and resistance at $3.34, providing a defined range for near-term movement.
The 30-day price range is $1.13 to $2.65, and annualized volatility is 100%. These levels suggest modest near-term drift with potential for movement toward the defined resistance if momentum builds.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.97 | $1.78 | $2.45 | 0% | Neutral | |
| $1.31 | $1.80 | $2.69 | +1% | Neutral | |
| $1.75 | $2.56 | $4.06 | +44% | Bullish | |
| $1.71 | $2.63 | $4.39 | +48% | Bullish | |
| $1.48 | $2.40 | $4.16 | +35% | Bullish | |
| $1.60 | $2.70 | $4.85 | +52% | Bullish | |
| $1.21 | $2.14 | $3.96 | +20% | Bullish | |
| $1.04 | $1.91 | $3.63 | +7% | Neutral | |
| $1.46 | $2.79 | $5.45 | +57% | Bullish | |
| $1.60 | $3.18 | $6.36 | +79% | Bullish | |
| $1.39 | $3.09 | $6.79 | +74% | Bullish | |
| $3.11 | $6.91 | $15.90 | +288% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.97 | $1.78 | $2.27 | +0.00% |
| August 2026 | $1.47 | $1.79 | $2.26 | +0.40% |
| September 2026 | $1.35 | $1.66 | $2.14 | -7.08% |
| October 2026 | $1.41 | $1.75 | $2.30 | +5.59% |
| November 2026 | $1.49 | $1.87 | $2.49 | +6.93% |
| December 2026 | $1.43 | $1.81 | $2.45 | -3.20% |
Click any year to see its month-by-month MTVA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MTVA could reach as high as $2.45, with a base case around $1.78 and support toward $0.97 — roughly 0% from $1.78. A consolidation phase looks the most probable path here.
Expect MTVA to range from $1.31 to $2.69 through 2027. The $1.80 average target implies a +1% move from current prices. That is up +1% on the projected 2026 average. Price action looks broadly range-bound.
The MTVA price prediction for 2028 points to an average of $2.56 (low $1.75, high $4.06) — a potential gain of +44% on today's $1.78. Buyers look set to stay in control over this stretch.
In 2029, MTVA is projected to trade between $1.71 and $4.39, averaging $2.63 — a potential gain of +48% from today's $1.78. That is up +3% on the projected 2028 average. Momentum favours further upside here.
MetaVia's 2030 outlook centres on $2.40, within a $1.48 to $4.16 range. That is -9% versus the projected 2029 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, MTVA could reach as high as $4.85, with a base case around $2.70 and support toward $1.60 — roughly +52% from $1.78. Momentum favours further upside here.
Expect MTVA to range from $1.21 to $3.96 through 2032. The $2.14 average target implies a +20% move from current prices. That is -21% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The MTVA price prediction for 2033 points to an average of $1.91 (low $1.04, high $3.63) — a potential gain of +7% on today's $1.78. Price action looks broadly range-bound.
In 2034, MTVA is projected to trade between $1.46 and $5.45, averaging $2.79 — a potential gain of +57% from today's $1.78. That is up +46% on the projected 2033 average. Buyers look set to stay in control over this stretch.
MetaVia's 2035 outlook centres on $3.18, within a $1.60 to $6.36 range. That is up +14% on the projected 2034 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2040, MTVA could reach as high as $6.79, with a base case around $3.09 and support toward $1.39 — roughly +74% from $1.78. Buyers look set to stay in control over this stretch.
Expect MTVA to range from $3.11 to $15.90 through 2050. The $6.91 average target implies a +288% move from current prices. That is up +123% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in MTVA today (≈ 561.797753 MTVA) could be worth
$3,884.6
+$2,884.6 (+288%) by 2050 · US Dollar
Based on the average projected MTVA price of $6.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MTVAwould be worth at today's price.
$1,000 invested in MTVA on Jul 10, 2025 (≈ 126.614337 MTVA) would be worth
$225.37
-$774.63 (-77.5%) today · 0.23× · US Dollar
Based on a MTVA entry price of $7.9 vs. today's $1.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.48 | $1,202.7 | +20.3% |
| 1 month ago | $1.96 | $908.16 | -9.2% |
| 3 months ago | $1.41 | $1,262.41 | +26.2% |
| 6 months ago | $8.17 | $217.95 | -78.2% |
| 1 year ago | $7.9 | $225.37 | -77.5% |
| All time (5.0y) ago | $7,761.6 | $0.23 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MTVA forecast.
Our base-case forecast reaches $3.60 around 2050.
Implied market cap at $3.60: $18.59M
The multi-year forecast shows a bullish trajectory beyond the near term. In 2030, the expected average price is $2.34 with a $35 ROI, following a path that includes a 2030 average and a higher long-run potential. By 2040, the forecast envisions an average of $3.00 with a 73.4% ROI, and by 2050 an average of $6.72 with a 288.2% ROI.
The maximum forecast in 2050 reaches $15.45, underscoring the potential for substantial upside under favorable conditions, while earlier years show more modest gains. These are estimates and not guarantees. The path depends on catalysts, market dynamics, and clinical outcomes which are not guaranteed to materialize as predicted.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.34 with a maximum of $4.05 and a minimum of $1.44, yielding a 35% ROI. The sentiment is BULLISH.
Forecasts indicate a bullish trajectory in the longer term with 2040 and 2050 forecasts showing higher averages and ROIs (2040 avg $3.00, ROI 73.4%; 2050 avg $6.72, ROI 288.2%), though nearer-term years include neutral sentiment and lower ROIs. Remember these are estimates, not guarantees.
Yes, the forecast for 2050 lists a max price of $15.45, indicating potential upside to $5 or $10 under favorable conditions.
Current price is $1.73 and market cap is $8.93M.
Sentiment: NEUTRAL. RSI14: 50. SMA50: $1.85. SMA200: $4.87. Support: $1.43. Resistance: $3.34. 30-day range: $1.13 to $2.65. Annualized volatility: 100%.
MetaVia Community Discussion
0Share your MetaVia price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.